earnings
confidence high
sentiment positive
materiality 0.70
Incyte Q1 2022 revenue $733M (+21%); Jakafi guidance raised; Opzelura uptake strong
INCYTE CORP
2022-Q1 EPS reported
$0.17
revenue$733,235,000
- Total product & royalty revenues $728M (+20% YoY); GAAP net income $38M ($0.17 EPS); non-GAAP net income $123M ($0.55).
- Jakafi net product rev $544M (+17% YoY); full-year guidance raised to $2.33-$2.40B from $2.3-$2.4B.
- Opzelura >38,000 new patients in Q1; 146M lives covered; vitiligo sNDA under FDA review, PDUFA July 18.
- Pemazyre approved in China; ruxolitinib QD NDA on track H1 2022; positive CHMP opinion for ruxolitinib in GVHD.
- Cash, equivalents & securities $2.5B as of March 31, 2022.